All In Biotech

Drug Trial Radar · NCT05289687

Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL

A Phase II Study of Daratumumab-Hyaluronidase for Chemotherapy-Relapsed/Refractory Minimal Residual Disease (MRD) in T Cell Acute Lymphoblastic Leukemia (T-ALL

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

20

Planned (sponsor's estimate)

Start

May 25, 2023

Primary completion

Jun 30, 2027

Study completion Jun 30, 2027

Sponsor

Lead sponsor
Eastern Cooperative Oncology GroupResearch network
Sponsor type
Research network
Collaborators
Janssen, LP
First posted
Mar 21, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In this study, the investigators are hypothesizing that daratumumab-hyaluronidase will effectively treat T-ALL in patients who have persistent or recurrent MRD following treatment with chemotherapy.

Conditions

  • T-cell Acute Lymphoblastic Leukemia

Interventions

  • Daratumumab / Hyaluronidase InjectionDrug

    Daratumumab-hyaluronidase 1800mg/ 30,000 units once weekly for 4 doses on Days 1, 8, 15, and 22

  • Daratumumab / Hyaluronidase InjectionDrug

    Patients that are MRD Negative on Day 29 will receive daratumumab-hyaluronidase 1800mg/ 30,000 units once weekly for 4 doses on Days 36, 43, 50, and 57.

  • Daratumumab / Hyaluronidase InjectionDrug

    Patients that remain MRD positive on Day 29 will receive a combination of daratumumab-hyaluronidase 1800mg/ 30,000 units once weekly for 4 doses on Days 36, 43, 50, and 57 and chemotherapy selected from the combinations listed below: * Cytarabine 3000 mg/m2, IV, Every 12 hours for 4 doses on Days 37 and 38 * Methotrexate 1000 mg/m2, IV, Over 24 hours on Day 36 OR * Methotrexate, Starting dose 100 mg/m2, IV, Days 36, 46, 56 * Vincristine, 1.5 mg/m2 (2 mg cap), IV, Days 36, 46, 56 * Pegaspargase, 2000 IU/m2 (Capped at 3750 IU), IV Days 37, 57 * Methotrexate 15 mg, IT, Days 36, 56

  • Daratumumab / Hyaluronidase InjectionDrug

    All patients with MRD negative response after completion of previous course are eligible for daratumumab-hyaluronidase 1800mg/ 30,000 units every 2 weeks on Days 1,15, 29, 43, 57, 71, 85, and 99 for 8 doses.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Complete Remission (CR)Time frame: Day 29
  2. Complete Remission (CR)Time frame: Day 64
  3. Complete Response with Partial Count Recovery (CRh)Time frame: Day 29
  4. Complete Response with Partial Count Recovery (CRh)Time frame: Day 64
  5. Complete Remission incomplete (CRi)Time frame: Day 29
  6. Complete Remission incomplete (CRi)Time frame: Day 64
  7. Minimal Residual Disease Negativity (MRD-)Time frame: Day 29
  8. Minimal Residual Disease Negativity (MRD-)Time frame: Day 64
  9. Morphologic RelapseTime frame: Day 29
  10. MRD RelapseTime frame: Day 29
  11. Morphologic RelapseTime frame: Day 64
  12. MRD RelapseTime frame: Day 64
  13. RefractoryTime frame: Day 29
  14. RefractoryTime frame: Day 64

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Northwestern

    Chicago, Illinois · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.